Small molecule approaches to treat autoimmune and inflammatory diseases (Part II): Nucleic acid sensing antagonists and inhibitors

  • Bioorg Med Chem Lett. 2021 Jul 15:44:128101. doi: 10.1016/j.bmcl.2021.128101.
Xiaoqing Wang  1 ,  Yafei Liu  1 ,  Xingchun Han  1 ,  Ge Zou  1 ,  Wei Zhu  1 ,  Hong Shen  1 ,  Haixia Liu  2
Affiliations
  • 1. Department of Medicinal Chemistry, Roche Innovation Center Shanghai, Roche Pharma Research and Early Development, Shanghai 201203, China.
  • 2. Department of Medicinal Chemistry, Roche Innovation Center Shanghai, Roche Pharma Research and Early Development, Shanghai 201203, China. Electronic address: [email protected].
PMID: 33984476 DOI: 10.1016/j.bmcl.2021.128101
Abstract

Nucleic acid sensing pathways play an important role in the innate immune system, protecting hosts against infections. However, a large body of evidence supports a close association between aberrant activation of those pathways and autoimmune and inflammatory diseases. Part II of the digest series on small molecule approaches to autoimmune and inflammatory diseases concentrates on recent advances with respect to small molecule antagonists or inhibitors of the nucleic acid sensing pathways, including endosomal TLRs, NLRP3 inflammasome and cGAS-STING.

Keywords
Autoimmune and inflammatory diseases; Inhibitors; Innate immunity; Nucleic acid; Small molecule antagonists.